Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research

PRINCETON, N.J., March 17 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: ) announced today that the followers clinical and preclinical
abstracts are expected to be the topic of unwritten or posting presentations at
the Annual Meeting of the American Association for Cancer Research (AACR),
being held April 12-16, 2008 in San Diego: -- "Dendritic and Deoxythymidine Monophosphate cell mathematical functions in patients with metastatic hormone-
refractory prostate gland gland malignant neoplastic disease treated with GVAX immunotherapy for prostate
malignant neoplastic disease and ipilimumab" (Abstract #2538, Clinical Immunotherapy Session)
- Oral presentation scheduled for Monday, April 14, 2008 at 1:25 p.m. -- "CTLA-4 encirclement for internal secretion refractory prostate gland cancer: dose-dependent
induction of CD8+ Deoxythymidine Monophosphate cell activation and clinical responses" (Abstract
#2539, Clinical Immunotherapy Session) - Oral presentation scheduled
for Monday, April 14, 2008 at 1:40 p.m. -- "Increased doses of an anti-CD30 antibody, MDX-060, consequences in
drawn-out patterned advance free endurance in topics with CD30 positive
lymphoma" (Abstract #5525, Phase 2 and 3 Clinical Trials 3: Blood,
Lung, Brain/CNS and Sarcoma Session) - Poster session scheduled for
Wednesday, April 16, 2008 at 8:00 a.m. -- "Preclinical development of anti B7-H4 curative antibodies"
(Abstract #4986, Developmental Immunotherapy Session) - Oral
presentation scheduled for Tuesday, April 15, 2008 at 2:25 p.m. -- "Human antibody conjugate solutions of possible public utility for prostate gland cancer
therapy: a comparing of MGBA conjugate solutions with antibodies targeting a
cell surface mark (prostate-specific membrane antigen) and an extra-
cellular mark (Mindin/RG1)" (Abstract #4062, Immunoconjugates,
Peptides, and Protein Therapeutics Session) - Poster session scheduled
for Tuesday, April 15, 2008 at 8:00 a.m. -- "Efficacy and safety of a human anti-CD70 antibody-MGBA conjugate"
(Abstract #4061, Immunoconjugates, Peptides, and Protein Therapeutics
Session) - Poster session scheduled for Tuesday, April 15, 2008 at 8:00
a.m. -- "Mechanism of activation of a human anti-CD70 antibody-MGBA conjugate
and efficaciousness in a bare rat theoretical account of nephritic carcinoma" (Abstract #4057,
Immunoconjugates, Peptides, and Protein Therapeutics Session) - Poster
session scheduled for Tuesday, April 15, 2008 at 8:00 a.m. -- "Ptk7 as a direct and tumour stroma mark in multiple solid
malignancies" (Abstract #1526, Targets and Screening Approaches
Session) - Poster session scheduled for Sunday, April 13, 2008 at 1:00
p.m. Abstracts and information about the AACR and its Annual Meeting may be
found at . About Medarex Medarex is a biopharmaceutical company focused on the discovery,
development and possible commercialisation of fully human antibody-based
therapeutics to handle life-threatening and debilitating diseases, including
cancer, inflammation, autoimmune upsets and infective diseases. Medarex
applies its UltiMAb(R) engineering and merchandise development and clinical
manufacturing experience to generate, support and potentially commercialize
a wide scope of fully human antibody merchandise campaigners for itself and its
partners. More than 40 of these curative merchandise campaigners derived from
Medarex engineering are in human clinical testing or have got had INDs submitted
for such as trials, with seven of the most advanced merchandise candidates
currently in Phase 3 clinical trials or the topic of regulatory
applications for selling authorization. Medarex is committed to building
value by developing a diverse grapevine of antibody merchandises to turn to the
world's unmet healthcare needs. For more than information about Medarex, visit
its website at . Medarex(R), the Medarex logotype and UltiMAb(R) are registered trademarks
of Medarex, Inc. All rights are reserved.

Nutrition Notes: Is Folate Helpful or Harmful for Cancer Prevention?

Washington, D.C. - American Institute for Cancer Research - infoZine - Folate, involved in the creative activity and fix of DNA, is critical in ensuring that our bodies' familial direction manual is read correctly. Damaged deoxyribonucleic acid can make alterations in factors that ease the growing and development of malignant neoplastic disease cells. Connect the points and it's easy to see why so much research is focused on the folate-cancer link. In the aforesaid study from the Swedish Malmo Diet and Cancer Study, women whose diets were highest in vitamin Bc (rich beginnings include dark greenness leafy vegetables, dried edible beans and fruit) were 44 percentage less likely to develop postmenopausal breast malignant neoplastic disease than women who ate the least vitamin Bc over the nearly ten-year study. Those with peak sum ingestion of vitamin Bc from nutrients plus folic acid (the word form establish in addendums and fortified food) showed a similar 41 percentage reduced hazard when compared to topics with the last intake. But the grounds is not always so straightforward. An analysis of 23 surveys on vitamin Bc and breast malignant neoplastic disease hazard establish mixed results. When women were separated according to alcoholic beverage consumption, however, dietary vitamin Bc had no impact on breast malignant neoplastic disease hazard among topics who rarely or never drank alcohol. Conversely, women who drank moderately (or more) and had a high vitamin Bc consumption reduced their breast malignant neoplastic disease hazard by almost 50 percent. This difference was noted even among those women who consumed one drink a twenty-four hours - an of import determination since at odds research proposes that even moderate imbibing can increase breast malignant neoplastic disease risk; perhaps a diet high in vitamin Bc can extenuate some of this hazard among women who devour alcohol. Yet, as is the nature of the scientific process, another analysis of 22 surveys relating vitamin Bc ingestion to breast malignant neoplastic disease hazard establish small if any impact. The former analysis investigated whether inherited differences might do vitamin Bc more of import for some women than others. Such difference, namely in the manner our factors modulate vitamin Bc metabolism, might explicate why vitamin Bc have an impact on malignant neoplastic disease hazard for some but not others (such a familial disagreement have already been noted for colon cancer). In the lawsuit of breast cancer, however, research workers were not able to demo a familial link. Still, other research is raising concerns that getting too much vitamin Bc could advance malignant neoplastic disease development. Lab surveys propose that once a little tumour or polypus have formed, other vitamin Bc may actually promote the aggressive growing of malignant neoplastic disease cells and silence so-called suppressor genes. Findings from the Aspirin/Folate Polyp Prevention Survey look to back up this hypothesis. Among nearly 1000 work force and women who previously had colon polypuses removed, those assigned to take 1000 mcgs (mcg) of folic acid developed 67 percentage more advanced polypuses than those pickings an inactive placebo. Note, however that the addendums taken were more than than two-and-a-half times the suggested mark for adults. The underside line: in the lawsuit of folate, research proposes that too much of a good thing may be detrimental. But take bosom - eating a healthy plant-based diet will not set you at hazard for extra folate. In the end, be aware of vitamin addendums and certain nutrition parallel bars or cereal grasses that supply 50 percentage or more than of the Daily Value for folate; you'd be surprised at how quickly they can add up. Instead, take natural nutrient beginnings of vitamin Bc that also supply the good vitamins, minerals and phytochemicals needed for overall malignant neoplastic disease protection.